Aardvark Therapeutics (AARD) Total Non-Current Liabilities (2024 - 2025)
Aardvark Therapeutics (AARD) posted Total Non-Current Liabilities of $10.5 million for Q4 2025, down 2.8% sequentially from $10.9 million in Q3 2025, and up 96.5% YoY from $5.4 million in Q4 2024.
Aardvark Therapeutics (AARD) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Aardvark Therapeutics has reported Total Non-Current Liabilities for 2 years, with the latest figure at $10.5 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 96.5% year-over-year to $10.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.5 million (up 96.5% YoY) and the FY2025 annual result came in at $10.5 million, up 96.5% from the prior year.
- Total Non-Current Liabilities slipped to $10.5 million in Q4 2025 per AARD's latest filing, from $10.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $10.9 million in Q3 2025 and troughed at $5.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Aardvark Therapeutics | 127.36 Mn | 53.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.55 Mn |
| Sep 30, 2025 | 10.85 Mn |
| Jun 30, 2025 | 10.54 Mn |
| Mar 31, 2025 | 6.31 Mn |
| Dec 31, 2024 | 5.37 Mn |